Kornimate/medical-research-clean huggingface dataset:
examination of a new non invasive sensor "lifebeam" during htt in protective clothing

Conditions: Heat Illness

Summary: cb (chemical biological)protective clothing provides a thermal resistance between the human body and its environment. cb protective clothing will be essential for combat soldiers in case of non conventional attacks. "lifebeam" developed a new non invasive sensor for body core temperature detection. the research purpose is to evaluate the "lifebeam" sensor during heat tolerance test while wearing cb protective clothing.


Eligibility criteria:
inclusion criteria: * age 21-30 * healthy * after medical checkup * after signing concent form exclusion criteria: * heart disease * respiratory disease * baseline bp above 140/90 mmhg * sleep disorders * diabetes * anhydrosis * skin disease * acute illness in last 3 days prior to the examination
an open-label, uncontrolled study of ono-4578 and ono-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this study is phaseⅰstudy to evaluate the tolerability and safety of ono-4578 and ono-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent nsclc who were refractory to a combination therapy containing an anti-pd-(l)1 antibody and a platinum-based drug


Eligibility criteria:
inclusion criteria: 1. clinical stage iii b/ iii c with unsuitable for radical irradiation, clinical stage iv or recurrent non-small cell lung cancer 2. life expectancy of at least 3 months 3. patients with ecog performance status 0 or 1 exclusion criteria: 1. patients with severe complication 2. patients with multiple primary cancers
effects of pyruvate in patients with cardiogenic shock and intra-aortic balloon counterpulsation

Conditions: Shock, Cardiogenic; Heart Failure; Acute Myocardial Infarction

Summary: pyruvate is an intermediate of energy metabolism and was shown to possess pronounced positive inotropic effects in vitro and in vivo without altering myocardial oxygen consumption. moreover, it was shown that the effects of beta-adrenergic stimulation were potentiated. thus, it might be possible to save catecholamines in patients with severe heart failure or cardiogenic shock. this study was designed to test the hemodynamic effects of pyruvate administered into a coronary artery in addition to intra-aortic balloon pump counterpulsation in patients with severe heart failure or in patients with acute myocardial infarction and cardiogenic shock after having performed percutaneous coronary intervention. a pronounced improvement in hemodynamics is expected to occur.


Eligibility criteria:
inclusion criteria: * hospitalized patients male/female * age: 18 - 85 years * weight: 45 - 110 kg * height 150 - 195 cm * clinically signs of heart failure (nyha iii-iv) refractary to therapy or cardiogenic shock in acute myocardial infarction * written informed consent or witnessed verbal consent or presumed will (compassionate use) exclusion criteria: * malignoma * clinically significant cardiac valve stenosis * participation in another clinical trial with relevant or probable drug-interactions * pregnancy or lactation * addiction * poor compliance

Keywords: pyruvic acid shock, cardiogenic catecholamines intra-aortic balloon pumping cardiac output cardiac index cardiac function
a study of capecitabine (xeloda) in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this study will evaluate the efficacy, safety, and pharmacoeconomics of oral capecitabine in patients with metastatic colorectal cancer. the anticipated time on study treatment is 3-12 months, and the target sample size is 28 individuals.


Eligibility criteria:
inclusion criteria: * adult patients greater than or equal to (\>=) 18 years of age * metastatic colorectal cancer exclusion criteria: * previous cytotoxic chemotherapy or immunotherapy for advanced or metastatic disease * central nervous system and bone metastases * moderate or severe renal impairment * clinically significant cardiac disease * lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication * malignancy within the last 5 years, except cured basal cell cancer of skin and cured cancer in situ of uterine cervix
mobile health to improve oral chemotherapy adherence among women with breast cancer

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Localized Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma; Metastatic Breast Cancer

Summary: this clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body (non-metastatic). a mobile health device, called smrxt smart pill bottle may help doctors to remind patients to take medicine on time and monitor their symptoms.

primary objectives: i. feasibility. ii. acceptability. iii. capecitabine/xeloda adherence. exploratory objectives: i. symptom burden. ii. patent physician communication. iii. quality of life. iv. self-efficacy for managing symptoms. outline: patients are randomized to 1 of 2 groups. group i: patients receive a smrxt smart pill bottle, report symptoms weekly, and receive reminders for missing or incorrect dose for standard of care 3-week capecitabine/xeloda treatment cycles. group ii: patients receive standard of care. after completion of study, patients are followed up for 90 days after the initiation of capecitabine/xeloda.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * breast cancer * english speaking * new or existing prescription for capecitabine/xeloda * willingness and ability of the subject to comply with study procedures * have a mobile phone with text message * evidence of an online informed consent indicating that the subject is aware of the risk and benefits of study participation exclusion criteria: * those who do not receive their capecitabine/xeloda prescription until a month after enrollment * eastern cooperative oncology group (ecog) performance status \> 2
effect of ivabradine on exercise capacity after heart transplantation

Conditions: Cardiac Allograft Vasculopathy; Transplanted Heart Complication

Summary: this study evaluates whether treatment with ivabradine compared to placebo can improve exercise capacity in long-term heart transplant recipients with cardiac allograft vasculopathy and elevated heart rate at rest. patients will receive treatment with either ivabradin or placebo for a period of 12 weeks.

elevated resting heart rate (hr) is a normal finding after successful heart transplantation (htx) due to parasympathetic denervation at the operation. elevated resting hr is generally acknowledged as a negative predictor of outcome in heart disease. the impact in heart transplant recipients is not fully understood, however, it has been associated with increased risk of developing cardiac allograft vasculopathy (cav) or death. cardiac allograft vasculopathy is a diffuse vascular disease affecting the entire coronary tree. it is the leading cause of death in patients more than 5 years after htx and it is well known that patients with cav have markedly reduced exercise capacity. the association between elevated hr and cav raises the question whether an intervention to specifically lower hr could improve symptoms and prognosis in heart transplant recipients with cav and elevated resting hr. small studies have shown that hr reduction using the if channel blocker ivabradine after htx is safe. however, none of these studies were randomized or blinded, and as such proof of any efficacy (beyond hr reduction) after htx is non-existing. clearly, there is a need to determine if such treatment could improve exercise capacity, graft function and prognosis after htx.

Eligibility criteria:
inclusion criteria: * patients \> 1 year post heart transplantation * cav verified by coronary angiography or intravascular ultrasound * resting hr \> 80 bpm * age \> 18 years * signed informed consent women, who have not yet entered menopause (defined as no menstrual bleeding in the last 12 months), will be required to provide a negative urine human chorionic gonadotropin (hcg) before entering the study and must use a safe birth control method in the total study period. exclusion criteria: * rejection (\>h1r) \< 3 months * severe renal failure (estimated glomerular filtration rate (gfr) \< 30 ml/min/1.73 m2) * inability or contraindication to perform a vo2 max test * presence of any condition that might per se influence exercise performance * known contraindication for treatment with ivabradine * hypersensitivity to the active substance or to any of the excipients of either study drug

Keywords: heart transplantation exercise capacity heart rate cardiac allograft vasculopathy
application of mr-pet in colorectal cancer

Conditions: Colorectal Cancer

Summary: this study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated mr-pet system and advanced mr techniques in patients with colorectal cancer.

this research expect that the image techniques and experience in this cancer group may be valuable and helpful for others. with advantage of mr-pet in better soft tissue delineation/functional information and less radiation dose than pet-ct, the ultimate goal in both research and clinical application is to establish new diagnostic standard and management guideline by mr-pet, which can further improve clinical outcome and disease prognosis in patients colorectal cancer.

Eligibility criteria:
inclusion criteria: 1. group 1: patients with newly diagnosed colorectal cancers 2. group 2: patients with suspicious recurrent colorectal cancers exclusion criteria: 1. age \ 90 years old 2. contraindication for mri: claustrophobia or mr non-compatible devices 3. contraindication for mr contrast medium: severe adverse reaction or impaired renal function (cre \> 2.0) 4. history of other malignancy 5. prior arthroplasty of hip (may cause artifacts on mri) 6. pregnancy

Keywords: application of mr-pet
total body vitamin a before and after vitamin a supplementation in a community where liver is frequently eaten

Conditions: Hypervitaminosis A

Summary: this study will assess total body vitamin a pool size, as well as liver vitamin a stores, by means of stable isotope dilution in preschool children from a south african community where liver, an exceptionally rich source of vitamin a, is frequently eaten, and the children exposed to vitamin a fortified staple foods, as well as a vitamin a supplementation programme.

serum retinol, the most commonly used indicator to assess vitamin a status, is homeostatically controlled and, although it is able to detect deficiency, it does not necessarily reflect liver stores or measure excessive vitamin a intake. the stable isotope dilution method is able to measure total vitamin a body pool size over the vitamin a status continuum, including the sub-toxic range,and would add valuable information about the vitamin a status in a community where liver (an exceptionally rich source of vitamin a) is frequently eaten, and children also exposed to other vitamin a interventions. total body vitamin a will be assessed before and 4 weeks after a high dose vitamin a supplement given to the children as part of the national vitamin a supplementation program. the confounding effect of infection/inflammation on the biomarkers of vitamin a status will also be examined, as well as how serum retinol and retinol binding protein relate to each other, and to vitamin a pool size.

Eligibility criteria:
inclusion criteria: * living in the study area; * must not have received a vitamin a supplement in the preceding month exclusion criteria: * severe anaemia (haemoglobin \< 9 g/dl); * fever (body temperature \> 38°c)

Keywords: vitamin a stores stable isotope dilution multiple vitamin a interventions
mild depression 2 week observational study

Conditions: Depressive Disorder

Summary: the purpose of this study is to assess whether the dysphoric-like depressive characteristics observed in people with epilepsy are unique to this patient population in comparison to three control groups: mild depression (enrolled at stanford university), migraine headaches (enrolled at long island jewish medical center), and multiple sclerosis (enrolled at rush university medical center).

this is a multicenter study consisting of a screen and retest phase conducted in two separate days separated by a two-week period. after providing written informed consent and meeting protocol-defined inclusion criteria at screen, patients will be administered the wide range achievement test 3 (wrat3) to ensure adequate word reading ability with which to complete the self-report forms. patients who achieve a satisfactory score will be interviewed using the mini international neuropsychiatric interview (mini). afterwards, each patient will first complete the 46 item mood and anxiety symptom list in epilepsy (mas-e) and then five additional questionnaires in random order. patients will also be given the opportunity to be rated by a proxy (e.g., caregiver, family member, friend) who will also complete the mas-e. patients will return the completed documents to the investigator and be given an additional mas-e to take home. in the retest phase, patients will be asked to complete the mas-e again exactly 14 days from the date of the screen visit. the proxy will also be given an additional mas-e and be asked to complete the mas-e exactly 14 days from completion of the first mas-e. the documents shall be returned to the clinic via u.s. mail on the same day of completion. it is not necessary to have a proxy to participate in this study. total study participation takes 2 weeks and approximately one visit to the clinic for the screening visit.

Eligibility criteria:
inclusion criteria:: " male or female 18 years of age or older. " presence of a depressive disorder that presents as a dysthymic or minor depressive disorder and whose score on the beck depression inventory (bdi) range between 11 and 20. patients with major depression will be excluded. " is currently on stable doses of medications i.e., no change in treatment in the previous 30 days. " achieves a satisfactory score on the wrat3 (standard score is \> 69). " is capable of completing the self-reporting questionnaires. " is willing and able to provide written informed consent and comply with the study protocol\&#xa; exclusion criteria:" presence of a clinically significant comorbidity of an unstable or progressive nature (e.g., psychosis, delirium) that could, in the opinion of the investigator, prevent completion of the questionnaires or warrant immediate medical intervention. " participation in an investigational trial within the past 30 days. " inability to communicate well with site study personnel, e.g. inability to read or understand english, poor mental development or impaired brain function. " patients with a clinical picture that meets criterion of major depression.
impact of quinoa milk fermented with lactic acid bacteria from foods on human oral and intestinal flora

Conditions: Microbial Colonization

Summary: the demand for alternatives to dairy products has increased in recent years and a lot of proposals for vegetable milk and yogurt products have taken place in the market. quinoa is a plant from south america that has growth in popularity in recent years as many sought out nutritious and healthier eating, the herb is known for its high nutritional value. it is complete protein source containing all the essential amino acids. if this herb were fermented with probiotic bacteria, there is a potential for a product that is lactose free, gluten free and cholesterol free. the probiotic potential of quinoa milk, fermented with food associated lactic acid bacteria will be investigated. this includes a study that examines how daily consumption of this vegetable drink changes the composition of the oral and intestinal flora. therefore, healthy people are now seeking to participate in the study, which will be for just over 2 weeks.


Eligibility criteria:
inclusion criteria: * above 18 years and healthy volunteers exclusion criteria: * participants that have any kind of diseases, such as colon inflammation
before colonoscopy effect of virtual reality application on anxiety and vital signs

Conditions: Colonoscopy

Summary: this study was planned to examine the effect of virtual reality application on the patient's anxiety and vital signs before colonoscopy. the hypotheses of the research are as follows: h1: virtual reality application before colonoscopy has an effect on patients' anxiety and vital signs. h0: virtual reality application before colonoscopy has no effect on patients' anxiety and vital signs. before colonoscopy, patients in the study group will be asked to watch videos using virtual reality glasses.

after obtaining the ethics committee and institutional permission for the research, the researcher was taken to the hospital for the colonoscopy procedure. he/she will introduce himself/herself to the patients and explain the purpose of the research. patients who volunteered to participate in the study informed consent will be obtained. data regarding the socio-demographic characteristics of the patients included in the patient introduction form the patient will be interviewed face to face, and data regarding the patients' clinical characteristics will be recorded from the patient file. colonoscopy data will begin to be collected from the first patient to undergo the procedure. anxiety and life assessment with vas 30 minutes before the procedure the findings will be considered. according to the randomization, the patient in the virtual reality glasses group was first asked by the researcher. it will be explained to the patient that he will wear the glasses for 30 minutes and watch a video before the procedure. by researcher 30 when the minute is up, the patient will be informed and asked to remove the glasses. no intervention was made to the patient in the control group. it will not be done. anxiety and vital signs were measured with vas 5-10 minutes before the procedure began in all patient groups. will be looked into. after each patient use, the virtual reality glasses will be cleaned and dried with alcohol-based cleaning material.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the research, * being literate, * be 18 years or older. exclusion criteria: * performing colonoscopy at the same time as endoscopy, * using any analgesic or anxiolytic, * having a visual or hearing impairment, * performing an emergency colonoscopy.

Keywords: virtual reality glasses surgical nursing colonoscopy
coronary vasomotor response after riociguat exposure

Conditions: Coronary Artery Disease

Summary: the aim of the study is to assess the effects of intracoronary riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.


Eligibility criteria:
inclusion criteria: * male and female patients with coronary artery disease exclusion criteria: * patents with coronary artery disease with \>/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery \[lad\], left circumflex coronary artery \[lcx\] or right coronary artery \[rca\]) undergoing cardiac catheterization

Keywords: coronary artery disease
efficacy and safety profile of cisatracurium besylate for iah

Conditions: Intra-abdominal Hypertension

Summary: this study is a randomized, double-blinded, controlled design. in this study, cisatracurium besylate was selected for treatment in intra-abdominal hypertension or abdominal compartment syndrome,accompanied with evaluating the effects on the duration of organ failure,length of hospital stay and mortality.to clarify the effect of cisatracurium besylate on iah/acs is of great significance to the clinical applications.

1. title: title: efficacy and safety profile of cisatracurium besylate on intra-abdominal hypertension: a randomized clinical trial 2. research center: single center 3. design of the research: a randomized, double-blind and parallel controlled study 4. object of the research: the patients over 18 years that intra-abdominal pressure over 12mmhg. 5. sample size of the research: a total of 80patients,40 cases in each group 6. interventions: participants in the test group received cisatracurium besylate 0.12mg/kg/hr continuous infusion during intubation.while participants in the control group was the same as the test group except for received the same volume of saline instead of cisatracurium besylate.tof-watch was used to monitor the function of nerve and muscle in two groups and the dose was adjusted according to the tof value. 7. the aim of the research:to investigate the effect of cisatracurium besylate on iintra-abdominal hypertension or abdominal compartment syndrome. 8. outcome #primary outcomes: mortality. secondary outcomes: duration of organ failure; time for enteral nutrition to reach the standard (30kcal/kg); mechanical ventilation time; length of hospital stay 9. the estimated duration of the study#1-2years

Eligibility criteria:
inclusion criteria: 1. intra-abdominal pressure≥12mmhg 2. age ≥18 years old 3. obtain informed consent. exclusion criteria: 1. pregnancy pancreatitis 2. patients who have undergone percutaneous puncture or surgical drainage before admission, and have undergone surgical decompression due to early abdominal hypertension 3. patients with a history of chronic organ dysfunction (such as uremia, copd, liver cirrhosis, heart failure, etc.) 4. those who refuse to participate in the research